[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Insel Gruppe AG, University Hospital Bern\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":703},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,153,0,25,[9,46,72,99,125,162,185,222,245,269,294,319,349,373,394,427,447,472,496,525,555,597,624,648,676],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100626368","in-hospital-cardiopulmonary-resuscitation-with-balloon-occlusion-of-the-descending-aorta-100626368",false,"NCT07434726","In-hospital Cardiopulmonary Resuscitation With Balloon Occlusion of the Descending Aorta","CPReboa: In-hospital Cardiopulmonary Resuscitation With Balloon Occlusion of the Descending Aorta","CPReboa","Inclusion criteria:\n\n* patients suffering from in hospital cardiac arrest (IHCA), including patients with out of hospital cardiac arrest (OHCA) and return of spontaneous circulation (ROSC), transported to the emergency department, where they suffer a second arrest (IHCA)\n* successful placement of a femoral artery introducer sheath\n* any electrical cardiac activity seen in the initial rhythm analysis\n* ongoing effort of resuscitation as determined by study-independent resuscitation lead\n\nExclusion criteria:\n\n* IHCA in the operating room, on intensive care unit or in the cardiac catheter laboratory\n* hospital visitors suffering from cardiac arrest\n* asystole seen in the initial rhythm analysis\n* (presumed) age under 18 years\n* known \"do not resuscitate\"-order\n* known or obvious pregnancy\n* traumatic cardiac arrest\n* known aortic pathologies that render cannulation impossible\n* known allergies to radiographic contrast agents","ALL","18 Years",{"count":21,"type":22},98,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study will test if a sustained Return of Spontaneous Circulation (ROSC) in patients with cardiac arrest is more frequent when patients receive advanced cardiac life support (ACLS) alone or when they receive ACLS plus a balloon occlusion of the thoracic aorta.",[28],"Cardiac Arrest",[28,30,31,32],"resuscitative endovascular occlusion of the aorta REBOA","cardio pulmonary resuscitation CPR","advanced cardiac life support ACLS","RECRUITING","2026-08-20",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":37},"2026-04-14",{"date":41,"type":22},"2030-12",{"name":43,"class":44},"Insel Gruppe AG, University Hospital Bern","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100652567","impact-of-subthalamic-nucleus-deep-brain-stimulation-on-cognitive-and-psychiatric-symptoms-in-parkinsons-disease-100652567","NCT07777419","Impact of Subthalamic Nucleus Deep Brain Stimulation on COGnitive and PSYchiatric Symptoms in Parkinson's Disease","PD-COGPSY-DBS","Inclusion Criteria:\n\n* Diagnosed with Parkinson's disease\n* Treated with subthalamic nucleus deep brain stimulation (STN-DBS)\n* For part I: General research consent for the analysis of routine clinical data\n* For part II of the study: ability to provide informed consent\n* native German or French speaker\n* Montreal Cognitive Assessment with score ≥ 20\n\nExclusion Criteria:\n\n* Atypical Parkinsonism\n* Other disease affecting the brain (e.g. Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, non-provoked epilepsy, brain tumour, etc.)\n* Haemorrhage during implantation of STN-DBS, which resulted in permanent cognitive or physical impairment\n* Schizophrenia, ongoing substance abuse, bipolar disorder or autism\n* For part II: Severe depressive disorder and\u002For suicidality\n* Insufficient quality or lack of brain imaging data pre and\u002For post STN-DBS","75 Years",{"count":55,"type":22},20,[25],"With this study, the investigators want to investigate how deep brain stimulation (DBS) affects various cognitive and psychiatric symptoms of Parkinson's disease (PD). In particular, they will examine whether stimulation of the left hemisphere has a different effect than stimulation of the right hemisphere on cognitive and psychiatric symptoms.",[59],"Parkinsons Disease (PD)",[61,62,63],"Deep Brain Stimulation","Neuropsychiatric symptoms","Cognition","NOT_YET_RECRUITING","2026-08-18",{"date":34,"type":37},{"date":68,"type":22},"2026-08-01",{"date":70,"type":22},"2028-12-31",{"name":43,"class":44},{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":45},"100558074","glp-1-ra-on-alcohol-consumption-metabolism-and-liver-parameters-in-patients-with-obesity-and-fatty-liver-disease-100558074","NCT06546384","GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease","Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease","GLP-1 RA","Inclusion Criteria:\n\n* BMI ≥ 35 kg\u002Fm² OR BMI ≥ 28 kg\u002Fm² in the case of weight-related co-morbidities (pre-diabetes or type 2 diabetes mellitus, hypertension, dyslipidemia).\n* Fatty liver disease (steatosis on ultrasound and\u002For CAP value on FS \\> 238 dB\u002Fm)\n* Age 18 - 80 years\n* Alcohol Use Disorder Identification Test-C Score \\>4 (AUDIT-C) Score ≥4 for women and ≥5 for men (as measured from AUDIT-questionnaire distributed in visit 1)\n* Sufficient skills for German or French language (written and spoken)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Active illicit substance use\n* AUDIT-score \\\u003C 5 (males)\u002F 4 (females) (as measured from AUDIT-questionnaire distributed in visit 1)\n* Current treatment with drugs against alcohol dependence (disulfiram, acamprosate, naltrexone, baclofen and nalmefene)\n* Any known contraindication to semaglutide\n* Presence or history of a hepatic or extrahepatic malignancy from the previous 6 months","80 Years",{"count":82,"type":22},64,[25],"There is evidence that alcoholic beverage consumption significantly interacts with food energy intake. Furthermore, there is accumulating evidence showing independent, combined, and modifying effects of alcohol and metabolic factors on the onset and progression of chronic liver disease. Preclinical and clinical data have showed that GLP-1 RA can decrease alcohol consumption, particularly in obese patients. Moreover there is evidence that semaglutide can improve the liver sinusoidal milieu in pre-clinical models of cirrhosis.\n\nIn this study, the investigators aim to assess if patients treated with semaglutide and receiving counselling will achieve a significantly higher alcohol abstinence compared to patients only receiving counselling.",[86,87,88],"Adiposity","Fatty Liver","Alcohol Use Disorder",[90,91],"GLP-1","Semaglutide",{"date":93,"type":37},"2026-08-19",{"date":95,"type":22},"2026-11-01",{"date":97,"type":22},"2027-04-30",{"name":43,"class":44},{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},"100514299","early-closure-of-left-atrial-appendage-for-patients-with-atrial-fibrillation-and-ischemic-stroke-despite-anticoagulation-therapy-100514299","NCT05976685","Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy","Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic StrokE Despite Anticoagulation Therapy","ELAPSE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent\n* Permanent, persistent, or paroxysmal spontaneous AF previously known or diagnosed during the index hospitalization.\n* Recent (≤3 months) symptomatic ischemic stroke.\n* Active and ongoing anticoagulation therapy at stroke onset assessed based on medical history (i.e. any therapeutic oral anticoagulation therapy \\[Vitamin K antagonist\u002FDOAC according to prescription recommendations for AF; inadequate low-dose DOAC therapy allowed for inclusion\\] not stopped\u002Fpaused for \\>48 hours due to any reason, i.e. medical intervention or non-adherence).\n* Active or planned long-term therapy with DOAC\n\nExclusion Criteria:\n\n* Contraindications to DOAC therapy\n* Life expectancy \\\u003C1 year according to the opinion of the investigator\n* Stroke due to: Ipsilateral intra\u002Fextracranial high-grade stenosis, Isolated lacunar stroke, Other well-defined stroke aetiologies (i.e., endocarditis, vasculitis, Reversible Cerebral Vasoconstriction Syndrome \\[RCVS\\], Posterior Reversible Encephalopathy Syndrome \\[PRES\\], cerebral sinus venous thrombosis)\n* Previous persistent foramen ovale or atrial septum defect closure.\n* Rheumatic heart disease\n* Severe heart valve disease that requires treatment (severe aortic stenosis or regurgitation, severe mitral stenosis or regurgitation).\n* Contraindications for TEE (relevant esophageal varices, esophageal stricture, history of esophageal cancer).\n* Cardiac or non-cardiac surgical procedure within 30 days of randomization\n* Enrolled in another investigation of a cardiovascular device or investigating secondary prevention therapy.\n* Severely reduced Left Ventricular Ejection Fraction (LVEF) \\\u003C30%.\n* Severe renal impairment as described in the summary of medicinal product characteristics for the chosen DOAC (e.g. rivaroxaban, apixaban and edoxaban creatinine clearance \\\u003C15 ml\u002Fmin; dabigatran creatinine clearance \\\u003C30 ml\u002Fmin).\n* Hypertrophic cardiomyopathy\n* Intracardiac tumor\n* Ventricular thrombus\n* Acute cardiac decompensation\n* LAA is obliterated or surgically ligated\n* Persistent proximal LAA thrombus despite 4 weeks of anticoagulation (if a proximal thrombus in the LAA is found, anticoagulation with vitamin K antagonist (INR 2.5-3.5) may be started, and if the thrombus disappears, the patient may be eligible for LAAO)\n* Pregnancy or breastfeeding (pregnancy test in urine or blood to be performed at screening for women of childbearing potential)",{"count":108,"type":22},482,[25],"Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and cardioembolic stroke due to AF is its major complication. Direct oral anticoagulants (DOAC) reduce the risk of cardioembolism in patients with AF. Despite DOAC therapy, there is a significant residual stroke risk of 1-2%\u002Fyear. Recent data from the Swiss Stroke Registry found 38% of patients with AF and ischemic stroke were on prior anticoagulant therapy (approximately 400 patients per year in Switzerland). The investigators found in a prior observational study, that patients with AF who have ischemic stroke despite anticoagulation are at increased risk of having another ischemic stroke (HR 1.6; 95% confidence interval, CI 1.1-2.1). Combining observational data from 11 international stroke centres, the investigators found that the majority of ischemic strokes despite anticoagulation in patients with AF is \"breakthrough\" cardioembolism (76% of patients) and only a minority of 24% is related to other causes unrelated to AF. Optimal secondary prevention strategy is unknown. The investigators have conducted two independent observational studies including together \\>4000 patients but did not identify any strategy (e.g. switch to different DOAC, additional antiplatelet therapy) that seems superior. A recent randomized controlled trial on surgical occlusion of the left atrial appendage (LAAO) found that LAAO may provide additional protection from ischaemic stroke in addition to oral anticoagulation. Triggered by this finding, the investigators performed a matched retrospective observational study and found that patients with AF and stroke despite anticoagulation who received a combined mechanical-pharmacological therapy (DOAC therapy + LAAO) had lower rates of adverse outcomes compared to those with DOAC therapy alone. Therefore, the investigators hypothesize that in patients with AF and ischemic stroke despite anticoagulant therapy, LAAO in addition to anticoagulation with a DOAC is superior to DOAC therapy alone. The investigators propose an international, multi-center randomized controlled two-arm trial to assess the effect of LAAO in patients with AF suffering from strokes despite anticoagulation therapy and without competing stroke etiology. The investigators will use the PROBE design with blinded endpoint assessment. The investigators will enrol patients with non-valvular AF and a recent ischemic stroke despite anticoagulation therapy at stroke onset. Patients will be randomized 1:1 to receive LAAO + DOAC therapy (experimental arm) or DOAC therapy alone (standard treatment arm). The primary endpoint is the first occurrence of a composite outcome of recurrent ischemic stroke, systemic embolism and cardiovascular death during follow-up. Secondary outcomes include individual components of the primary composite outcome, safety outcomes (i.e. symptomatic intracranial haemorrhage, major extracranial bleeding, serious device- or procedure-related complication), functional outcome (modified Rankin Scale) and patient-oriented outcomes. The minimum follow-up is 6 months and all patients will receive follow-ups every 6 months until end of study, the maximal follow-up will be 48 months. Based on prior observational data from the investigators' group and others (5 observational studies, \\>5000 patients), the investigators estimate the proportion of patients with the primary outcome in the standard treatment arm to be 18% in the first year and 9% in the second year (=cumulative 27% after 2 years). A relative risk reduction of 40% at 2 years would be clinically relevant. Based on these assumptions and a log-rank test, the investigators would need 98 events for a power of 80% at an alpha-level of 5%. Assuming a recruitment rate of 52, 118, 156 and 156 patients in years 1 to 4, an additional 6 months of follow-up (mean follow-up time of 2.1 years) and a uniform drop-out rate of 7.5% per year, 482 patients would need to be enrolled. How to treat patients with an ischemic stroke despite anticoagulation is a major yet unresolved clinical dilemma. This trial has the potential to answer the question whether LAAO plus DOAC therapy is superior to current standard of care for patients with AF who have ischemic stroke despite anticoagulation.",[112,113],"Ischemic Stroke","Atrial Fibrillation",[115,116,117],"Stroke","Direct oral anticoagulation","Left atrial appendage occlusion",{"date":34,"type":37},{"date":120,"type":37},"2024-05-01",{"date":122,"type":22},"2028-06-01",{"name":43,"class":44},31,{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":45},"100429619","phase-1-direct-oral-anticoagulants-rivaroxaban-and-apixaban-in-patients-with-liver-cirrhosis-100429619","NCT04874428","Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis","Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban and Apixaban in Patients With Compensated Liver Cirrhosis","Inclusion Criteria:\n\n* Age 18 years or older\n* Patient with previously diagnosed liver cirrhosis (Child-Pugh score grade A and B).\n* Written informed consent\n\nExclusion Criteria:\n\n* Positive pregnancy test (only for women in childbearing age with intact uterus), pregnancy or nursing women\n* Intake of prophylactic or therapeutic oral anticoagulant (phenprocoumon, acenocoumarol, dabigatran etc.) 2 weeks prior to inclusion in the study\n* Application of parenteral anticoagulant, e.g. unfractionated heparin, low molecular weight heparins, heparin derivatives (fondaparinux etc.) 1 week prior to inclusion in the study\n* Pharmacologic platelet inhibition within 2 weeks prior to inclusion in the study\n* Known coagulation disorders (e.g. von Willebrand's disease, hemophilia)\n* Active, clinically significant bleeding\n* Congenital or acquired bleeding disorder\n* High risk of bleeding (e.g. active ulcerative gastrointestinal disease)\n* Uncontrolled severe hypertension\n* Vascular retinopathy\n* Acute infection\n* Acute bacterial endocarditis\n* Severe anemia (haemoglobin ≤100 g\u002FL)\n* Hereditary galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption\n* Severe liver dysfunction (Child-Pugh Score grade C)\n* Hepatic encephalopathy ≥ grade 3\n* Severe renal impairment with a creatinine clearance (GFR) of \\\u003C30 ml\u002Fmin\n* Known intolerance to the study medications rivaroxaban and\u002For apixaban\n* Concomitant treatment with a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, lopinavir, ritonavir, indinavir).\n* Concomitant treatment with a P-glycoprotein inhibitor and a weak or moderate CYP3A4 inhibitor (e.g., erythromycin, azithromycin, diltiazem, verapamil, quinidine, ranolazine, dronedarone, amiodarone, felodipine).\n* Concomitant treatment with a P-glycoprotein inducer and a strong CYP3A4 inducer (e.g., carbamazepine, phenytoin, rifampicin).\n* Wash-out period of less than two weeks prior to the application of study drug in case of prior treatment with a strong CYP3A4 inhibitor or a P-glycoprotein inhibitor and weak or moderate CYP3A4 inhibitor or with a P-glycoprotein inducer or strong CYP3A4 inducer.",{"count":133,"type":22},24,[135],"PHASE1","The aim of this study is to investigate the pharmacokinetic and pharmacodynamic parameters of rivaroxaban and apixaban in patients with compensated liver cirrhosis (Child-Pugh class A and B).\n\nThe enrolled participants receive a prophylactic single oral dose of either rivaroxaban (10 mg) or apixaban (2.5 mg) at around 8 a.m. on the day of the trial. Blood samples are taken 0.5 hours pre-dose and 1, 2, 3, 4, 6, 8, 12 hours post-dose.\n\nA follow-up telephone call is performed 5 days after the study intervention to collect safety data.",[138],"Liver Cirrhosis",[140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,138,155],"Rivaroxaban","Apixaban","Factor Xa Inhibitors","Antithrombins","Serine Proteinase Inhibitors","Protease Inhibitors","Enzyme Inhibitors","Anticoagulants","Pharmacokinetics","Pharmacodynamics","Thromboembolism","Venous Thromboembolism","Embolism and Thrombosis","Vascular Diseases","Cardiovascular Diseases","Liver Diseases",{"date":93,"type":37},{"date":158,"type":37},"2021-05-19",{"date":160,"type":22},"2026-12",{"name":43,"class":44},{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},"100577715","topanc-trial-survival-after-total-versus-partial-pancreaticoduodenectomy-for-adenocarcinoma-of-the-pancreatic-head-distal-cholangiocarcinoma-and-ampullary-cancer-100577715","NCT06801899","ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer","ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer: a Multi-centric Randomized Controlled Trial","ToPanc","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years) scheduled to undergo PD for highly suspected or histologically proven, resectable pancreatic ductal adenocarcinoma (PDAC), distal cholangiocarcinoma (DCC), and\u002For ampullary cancer (pancreaticobiliary type)\n* Suspected pancreas anastomosis at high-risk for development of a postoperative pancreatic fistula (POPF) (grade \"D\" according to Schuh et al. (29): Estimation by CT scan, MRI, and\u002For Endoscopic Ultrasound\n* Written informed consent\n\nExclusion Criteria:\n\n* Duodenal carcinoma, ampullary cancer (intestinal type), neuroendocrine tumors, benign tumors, chronic pancreatitis\n* Medical conditions that do not allow appreciation of the nature, scope, and possible consequences of the trial as judged by the investigator\n* Pregnancy. A beta-Human Chorionic Gonadotropin (bHCG) pregnancy test must to be performed for women of child-bearing potential (defined as premenopausal women who have not undergone surgical sterilization)\n* Inability to follow the study procedures, e.g., due to psychological disorders, dementia, etc.",{"count":171,"type":22},170,[25],"The goal of this clinical trial is to learn if total removal of the pancreas is a preferable alternative to partial removal in patients with cancer of the pancreatic head who are at high risk of pancreatic leakage. The main question it aims to answer is:\n\nDoes total pancreas removal improve survival without reducing quality of life compared to partial removal?\n\nThe only study specific procedures are the collection of 2 blood samples (7.5ml for each time point, preoperatively and during the hospitalisation) and the completion of the questionnaires.",[175],"Pancreatic Cancer","2026-08-10",{"date":178,"type":37},"2026-08-12",{"date":180,"type":37},"2026-06-01",{"date":182,"type":22},"2030-10",{"name":43,"class":44},10,{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":193,"sex":18,"minAge":194,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":197,"phases":4,"briefSummary":198,"conditions":199,"keywords":206,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":221},"100633235","giving-children-a-voice-in-paediatric-anaesthesia-100633235","NCT07524049","Giving Children a Voice in Paediatric Anaesthesia","Patient, Parent and Clinician Voices - Establishing National and International Research Priorities for Paediatric Anaesthesia and Perioperative Medicine","TR-VP26","Inclusion Criteria:\n\n* Patients aged 6-16 years\n* Caregivers of patients aged 6-16 years\n* Clinicians working in paediatric perioperative medicine\n\nExclusion Criteria:\n\n* Patients \\\u003C6 and \\>16 years\n* Residence not in Switzerland\n* Inability to understand one of the 3 study languages (german, french, italian)",true,"6 Years",{"count":196,"type":22},1040,"OBSERVATIONAL","This project will identify the research priorities for paediatric anaesthesia and perioperative medicine in participating countries and highlight areas where further research and information can be provided to optimise the experience of children undergoing medical interventions.\n\nThis is expected to have significant positive impacts on patient and family engagement and interest in research within the community and aids to plan patient\u002F family-centred studies.",[200,201,202,203,204,205],"Perioperative Care","Pediatric Anesthesia","Pain Management","Anxiety","Research Agenda","Research Subjects",[207,208,209,210,211,212],"perioperative medicine","pediatric anesthesia","patient perspective","parent perspective","research priorities","survey","2026-08-06",{"date":215,"type":37},"2026-08-11",{"date":217,"type":37},"2026-05-27",{"date":219,"type":22},"2027-12-31",{"name":43,"class":44},7,{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":244},"100562957","supraglottic-jet-ventilation-vs-high-flow-nasal-oxygen-in-tubeless-laryngotracheal-surgery-100562957","NCT06609915","SuprAglottic Jet Ventilation vs High-flow Nasal Oxygen in Tubeless Laryngotracheal Surgery","SuprAglottic superImposed High Frequency Jet Ventilation veRsus High-flow nAsal oxYgen in Tubeless Laryngotracheal Surgery (AIRWAY): a Prospective Randomised Controlled Trial","AIRWAY","Inclusion Criteria:\n\n* Written informed consent\n* Patients aged ≥18 years\n* Patients requiring elective tubeless laryngotracheal surgery\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years\n* High risk of aspiration which concludes the consideration of using a tube in order to prevent aspiration.",{"count":231,"type":22},40,[25],"This study aims to investigate two oxygenation methods (high flow nasal oxygen and supraglottic, superimposed high-frequency jet ventilation) for tubeless laryngotracheal surgeries concerning their safety and efficiency.",[235,236],"Airway Managment","Laryngotracheal Surgery",{"date":238,"type":37},"2026-08-07",{"date":240,"type":22},"2026-10-01",{"date":242,"type":22},"2029-04-01",{"name":43,"class":44},2,{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":193,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":23,"phases":252,"briefSummary":253,"conditions":254,"keywords":259,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":266,"leadSponsor":268,"locationsCount":45},"100619715","pharmacokinetics-and-pharmacodynamics-of-synthetic-nicotine-and-nicotine-analogues-100619715","NCT07348224","Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine and Nicotine Analogues","Inclusion Criteria:\n\n* Men or women, age 18 or older at screening who have used EC with nicotine during at least 10 of the past 30 days\n* Saliva cotinine concentration of \\> 30 ng\u002FmL at screening\n* Ability to communicate well with the investigator and to understand and comply with the requirements of the study\n* Women of child-bearing age engaging in sexual activities which can lead to pregnancy: willingness of using a reliable\u002Fhormonal contraception method during the study (hormonal, e.g. pill, intrauterine devices, or mechanical method, e.g. condom, diaphragm)\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Known hypersensitivity\u002Fallergy to a content of the e-liquids\n* Smoking of more than 5 cigarettes per day in the past 30 days\n* Pregnant or lactating women\n* Intention to become pregnant during the course of the study\n* BMI \\\u003C 18 or \\> 30 kg\u002Fm2 at screening\n* History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening\n* Loss of ≥ 250 mL of blood within 3 months prior to screening, including blood donation\n* Treatment with an investigational drug within 30 days prior to screening\n* Treatment with prescribed or over-the-counter medications with known influence on CYP2A6 function within 1 week prior to screening (with the exception of contraception)\n* History or clinical evidence of any disease (e.g. gastrointestinal tract-disease) and\u002For existence of any surgical or medical condition, which in the opinion of the investigator might interfere with the absorption, distribution, metabolism or excretion of the study drugs, or which might increase the risk of toxicity.\n* Legal incapacity or limited legal capacity at screening\n* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol",{"count":133,"type":22},[25],"Electronic cigarettes are battery-operated devices that can produce an aerosol by heating a liquid which commonly contains nicotine. In recent years, products containing synthetically produced nicotine and nicotine analogues have entered the market. However, it remains unclear whether these types of nicotine have the same effects as conventional nicotine derived from the tobacco plant. The aim of this study is to investigate the effects of these nicotine types and to gain a better understanding of their respective mechanisms of action.",[255,256,257,258],"Nicotine","Vaping","Synthetic Nicotine","Nicotine Analogues",[260,261,262],"synthetic nicotine","nicotine analogues","vaping","2026-08-05",{"date":213,"type":37},{"date":263,"type":22},{"date":267,"type":22},"2026-12-31",{"name":43,"class":44},{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":278,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":45},"100624902","motor-eloquent-navigated-transcranial-magnetic-stimulation-for-radiosurgery-planning-100624902","NCT07415668","Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning","MENTOR","Inclusion Criteria:\n\n1. Informed consent\n2. Age ≥ 18 years\n3. Cerebral metastasis within or adjacent to the primary motor cortex (≤10 mm)\n4. Resection of tumor\n5. Eligible for and planned to undergo postresection radiosurgery at Inselspital Bern\n\nExclusion Criteria:\n\n1. Contraindication to TMS (e.g. Cochlear Implant, other metallic or electrical implants, excluding teeth and post craniotomy, Meniere's disease, pacemaker, deep brain stimulation electrodes, refractory convulsion, symptomatic tinnitus, depression diagnosed by a specialist, psychosis)\n2. Prior cerebral radiation therapy within the affected precentral gyrus\u002Faffecting the planned SRS plan\n3. Planned whole brain radiotherapy\n4. Second lesion within 2 cm ipsilateral in the primary motor cortex\n5. Infection or difficulties in wound healing within the last two weeks prior inclusion\n6. Pregnancy",{"count":277,"type":22},30,[25],"With this project, the study group wants to investigate whether a postoperative navigated transcranial magnetic stimulation (nTMS) motor map can improve stereotactic radiosurgery (SRS) planning in patients who underwent resection for a brain metastasis near the primary motor cortex. Specifically, the map could allow for more precise location of motor eloquent tissue, thereby minimizing the radiation dose on these areas while preserving high radiation dose on target tissue (i.e. tumor cells).",[281],"Metastases to Brain",[283,284,285],"metastasis","Navigated Transcranial Magnetic Stimulation (nTMS)","Stereotactic Radiosurgery (SRS)","2026-08-03",{"date":288,"type":37},"2026-08-04",{"date":290,"type":37},"2026-05-08",{"date":292,"type":22},"2029-10-31",{"name":43,"class":44},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":304,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":318},"100566327","phase-3-trial-to-assess-the-efficacy-of-empagliflozin-and-personalized-dietary-counseling-for-kidney-stone-prevention-100566327","NCT06653738","Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention","Randomized Placebo-controlled Trial to Assess Efficacies of EMPAgliflozin and Personalized Dietary Counselling for Kidney STONE Prevention in Patients With Calcium Kidney Stones Acronym: EMPASTONE Trial","EMPASTONE","Inclusion criteria:\n\n1. Written, informed consent.\n2. Age 18 years or older.\n3. Recurrent kidney stone disease with 2 or more stone episodes in the last 10 years prior to randomization.\n4. Last kidney stone containing 50% or more of CaOx, CaP or a mixture of both.\n5. If taking guideline-recommended medications for kidney stone prophylaxis (e.g. citrate salts), patients must have been on a stable regimen for at least 60 days before randomization and willing to remain on this stable regimen for the duration of the study.\n\nExclusion criteria:\n\n1. Known history of secondary or Mendelian causes of calcium nephrolithiasis\n2. Type I diabetes mellitus\n3. History of ketoacidosis\n4. Chronic Kidney Disease (CKD) stage 4 or 5 (defined as CKD-EPI eGFR \\\u003C30 mL\u002Fmin)\n5. Kidney transplant recipient\n6. History of recurrent urinary tract infections, defined as \\>3 episodes within the year prior to randomization\n7. Heart failure. Symptomatic patients with suspected heart failure must be evaluated before study enrollment\n8. Treatment with an SGLT2i within 4 weeks prior to randomization.\n9. Active cancer treatment\n10. Pregnancy and\u002For breastfeeding. Women of childbearing potential (i.e., premenopausal women who have not undergone surgical sterilization and are sexually active with a male partner) must have a negative urine or blood pregnancy test prior to enrollment\n11. Known allergy to the study drug\n12. Inability to understand and follow the study procedures\n13. Vulnerable individual, e.g. individual incapable of judgement or currently incarcerated or otherwise institutionalized (priosner), or refugee\n14. Concomitant participation in another interventional clinical trial within 4 weeks prior to randomization and during the current trial\n15. Prior enrollment in the EMPASTONE trial",{"count":303,"type":22},400,[305],"PHASE3","The aim of this randomized trial with a 2-by-2 factorial design is to test the efficacy of the SGLT2 inhibitor empagliflozin and personalized dietary counseling based on 24-hr urine collection results and dietary assessments for kidney stone recurrence prevention in patients with calcium kidney stones.\n\nStudy interventions:\n\n* Empagliflozin 10 mg once daily per os for 36 months\n* Personalized dietary counseling for 36 months.\n\nControl interventions:\n\n* Placebo once daily per os for 36 months\n* Generic dietary counseling for 36 months.",[308,309,310],"Kidney Stone","Nephrolithiasis","Dietary Exposure","2026-07-30",{"date":286,"type":37},{"date":314,"type":37},"2026-07-02",{"date":316,"type":22},"2030-09",{"name":43,"class":44},21,{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":23,"phases":329,"briefSummary":331,"conditions":332,"keywords":333,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":348},"100559977","phase-4-safety-and-efficacy-of-intravenous-thrombolysis-in-patients-with-ischemic-stroke-and-direct-oral-anticoagulants-intake-100559977","NCT06571149","Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake","Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke on Treatment With Direct Oral Anticoagulants: DO-IT - The DOAC Intravenous Thrombolysis Trial","DO-IT","Inclusion Criteria:\n\n* Informed consent (deferred consent when possible according to national legislation)\n* AIS eligible to receive intravenous alteplase\u002Ftenecteplase as per standard of care disabling according to the judgement of the treating physician\n* DOAC ingestion within 48 hours prior to enrollment, or patient with an ongoing prescription of DOAC but exact time point of last intake is unknown.\n* Either\n\n  * Can be randomized within 4 hours 15 minutes and treated within 4 hours 30 minutes of last known well time OR\n  * MRI showing a pattern of \"DWI-FLAIR-mismatch\", i.e. acute ischemic lesion visibly on DWI (\"positive DWI\") but no marked parenchymal hyperintensity visible on FLAIR (\"negative FLAIR\") indicative of an acute ischemic lesion ≤4.5 hours of age AND Treatment can be started within 4.5 hours of symptom recognition (e.g., awakening).\n\nExclusion Criteria:\n\n* Contra-indications to IVT by the current standard of care of the treating physicians with the exception of recent DOAC intake as specified above.\n* Intended reversal by specific or unspecific reversal agents\n* Pregnancy or lactating women. To be reasonable sure to exclude women with ongoing pregnancy, women are not considered of childbearing potential if they fulfill the following criteria\n\n  * Age \\> 55 years OR\n  * Age \\\u003C 55 years and at least 12 months since last menstrual period OR\n  * Have had a documented surgical sterilization\n* Patient \\\u003C 18 years of age (since the benefit of IVT is unproven in this population)\n\nSince the benefit of IVT might be smaller in patients in which additional endovascular treatment is planned, the investigators will cap patients with intended mechanical thrombectomy at 20% of the trial population. If this number is reached, the following additional exclusion criterion will be applied:\n\n* Intended treatment with endovascular reperfusion strategies",{"count":328,"type":22},906,[330],"PHASE4","DO-IT is an international, multicenter, prospective, two-arm, randomized, open label, blinded endpoint superiority trial determining the safety and efficacy of intravenous thrombolysis (IVT) in participants experiencing an acute ischemic stroke (AIS) with recent (within the last 48 hours) intake of direct oral anticoagulant (DOAC). For this purpose, 906 adult participants experiencing an AIS with recent DOAC intake will be enrolled at several high-volume international stroke centers and randomly assigned in a ratio of 1:1 to one of two treatment arms: (1) IVT and standard of care\u002Fbest medical treatment or (2) standard of care\u002Fbest medical treatment. The DO-IT trial is a definitive test of the hypothesis that IVT is superior to standard of care for achieving better outcome at 90 days in AIS participants with recent DOAC intake.",[112],[334,335,336,337,338,339,140,141,340,341],"DOAC","NOAC (Novel Oral Anticoagulants)","Anticoagulation","r-tPA (tissue-type plasminogen activator)","Alteplase","Tenecteplase","Dabigatran","Edoxaban",{"date":286,"type":37},{"date":344,"type":37},"2025-03-14",{"date":346,"type":22},"2029-04-30",{"name":43,"class":44},102,{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":197,"phases":4,"briefSummary":358,"conditions":359,"keywords":363,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":45},"100635625","night-to-night-variability-of-novel-physiological-parameters-in-home-sleep-apnea-testing-100635625","NCT07555119","Night-to-Night Variability of Novel Physiological Parameters in Home Sleep Apnea Testing","N2N-OSA","Inclusion Criteria:\n\n* Patients with suspected or diagnosed sleep-disordered breathing, irrespective of disease severity, as defined by the indications for home sleep apnea testing in the German guidelines \\[15\\]\n* No active treatment during sleep recordings or within preceding two weeks (e.g., mandibular advancement devices, positive airway pressure therapy)\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Known or suspected neurological sleep disorder (e.g., narcolepsy, parasomnia)\n* Known or suspected psychiatric sleep disorder\n* Known or suspected central and complex sleep apnea\n* Participants who are unable to perform sleep measurements reliably\n* Insufficient knowledge of the project language (German)\n* Inability to give consent\n* Shift workers (with shift work \\\u003C2 weeks before testing)",{"count":357,"type":22},192,"Obstructive sleep apnea (OSA) is usually diagnosed from a single night of home sleep apnea testing using the apnea-hypopnea index (AHI). However, the AHI varies substantially from night to night, undermining diagnostic accuracy, and shows only modest correlation with symptoms. This variability further limits its usefulness for predicting cardiovascular and other complications. Besides the traditional AHI, more robust physiological markers are needed.\n\nSeveral emerging physiological metrics - hypoxic burden, ventilatory burden, heart rate variability, autonomic arousals, and the pulse wave amplitude drop index - capture the physiological impact of OSA more comprehensively and demonstrate stronger associations with cardiovascular risk. Despite this promise, their night-to-night variability has not been studied.\n\nA systematic evaluation of both established and novel OSA metrics across nights is essential to identify reliable, stable parameters suitable for clinical routine. This improves diagnostic precision beyond what traditional metrics can provide, enhances patient selection, reduces costs and patient harm, and may improve treatment outcomes.",[360,361,362],"Obstructive Apnea","Diagnostic","Sleep Apnea Syndrome (OSAS)",[364],"Home Sleep Apnea Testing","2026-07-28",{"date":367,"type":37},"2026-07-29",{"date":369,"type":37},"2026-07-24",{"date":371,"type":22},"2027-06-30",{"name":43,"class":44},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":379,"targetDuration":381,"studyType":197,"phases":4,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":45},"100648117","building-a-swiss-pain-registry-a-national-framework-for-acute-and-chronic-pain-assessment-100648117","NCT07717762","Building a Swiss Pain Registry: A National Framework for Acute and Chronic Pain Assessment","Inclusion Criteria:\n\n* Signed informed consent by the participant or legal guardian for minors.\n* Diagnosis of acute or chronic pain (chronic pain defined as pain lasting ≥ 3 months), including nociceptive, neuropathic, or mixed pain conditions.\n* Referral for interdisciplinary outpatient pain assessment or treatment.\n* Sufficient proficiency in German, French, Italian, or English to complete digital assessments (parental proxy allowed for paediatric participants if needed).\n* All age groups included.\n\nExclusion Criteria:\n\n* Lack of capacity to provide informed consent or absence of a legal guardian for minors.\n* Inability to understand study languages and complete assessments even with assistance.\n* Acute life-threatening conditions precluding participation.\n* Site-specific safety considerations as determined by treating clinician.",{"count":380,"type":22},500,"24 Months","The goal of this observational registry is to systematically collect and analyse real-world clinical and patient-reported data in individuals receiving treatment for acute and chronic pain. The main questions it aims to answer are: How do pain intensity, functional status, and quality of life evolve over time in patients with acute and chronic pain? How are different routine clinical treatment approaches associated with patient-reported outcomes in real-world clinical practice? Participants already receiving standard care for pain management will have routine clinical data recorded as part of their treatment and will be asked to complete standardized questionnaires on pain intensity, functional status, and quality of life at multiple time points during treatment and follow-up. Data are collected using a secure electronic system and are pseudonymised prior to analysis in accordance with Swiss data protection regulations.",[384,385],"Chronic Pain","Acute Pain","2026-07-16",{"date":388,"type":37},"2026-07-21",{"date":390,"type":22},"2026-07-15",{"date":392,"type":22},"2029-08-15",{"name":43,"class":44},{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":402,"minAge":19,"maxAge":403,"enrollmentInfo":404,"targetDuration":4,"studyType":23,"phases":406,"briefSummary":407,"conditions":408,"keywords":411,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":45},"100647622","histological-assessment-of-tissue-penetration-depth-of-argon-beam-coagulation-in-ovarian-endometriomas-100647622","NCT07711743","Histological Assessment of Tissue Penetration Depth of Argon Beam Coagulation in Ovarian Endometriomas","Histological Assessment of Tissue Penetration Depth of Argon Beam Coagulation in Ovarian Endometriomas: A Prospective Pilot Study","ENDO-ARGON","Inclusion Criteria:\n\n* Female patients aged 18-40 years.\n* Indication for surgical treatment of ovarian endometrioma based on clinical symptoms and\u002For imaging findings.\n* Diagnosis of ovarian endometrioma ≥3 cm confirmed by preoperative imaging (ultrasound and\u002For MRI).\n* Planned laparoscopic cystectomy.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Expected lack of compliance or inability to understand the study procedures.\n* Previous surgical procedures on the affected ovary.\n* Recurrent ovarian endometrioma.\n* Pregnancy or breastfeeding.\n* Participation in another interventional clinical study that may influence study outcomes, such as anti-Müllerian hormone (AMH) levels or pregnancy.","FEMALE","40 Years",{"count":405,"type":22},50,[25],"The goal of this clinical trial is to evaluate the depth of tissue penetration of Argon Beam Coagulation (ABC) during laparoscopic surgery for ovarian endometriomas. Researchers want to determine how deeply ABC affects ovarian tissue and to generate data on the safety of this surgical technique.\n\nParticipants will undergo standard laparoscopic surgery for ovarian endometriomas. During the planned surgical procedure, Argon Beam Coagulation will be applied to the ovarian surface according to the study protocol. The treated tissue will subsequently be excised as part of the planned surgery and analyzed histologically to measure the depth of tissue penetration.",[409,410],"Ovarian Endometrioma","Endometriosis",[412,409,410,413,414,415,416,417,418],"Argon Beam Coagulation","Laparoscopy","Histopathology","Tissue Penetration","Ovarian Cystectomy","Fertility Preservation","Ovarian Reserve","2026-07-13",{"date":421,"type":37},"2026-07-17",{"date":423,"type":37},"2026-07-09",{"date":425,"type":22},"2027-08-07",{"name":43,"class":44},{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":434,"enrollmentInfo":435,"targetDuration":4,"studyType":23,"phases":436,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":45},"100565914","maximal-medical-treatment-of-intracerebral-haemorrhage-pilot-trial---max-ich-pilot-trial-100565914","NCT06648369","Maximal Medical Treatment of Intracerebral Haemorrhage Pilot Trial - MAX-ICH Pilot Trial","MAX-ICH","Inclusion Criteria:\n\n* Symptomatic imaging proven diagnosis of non-traumatic ICH\n* Vascular imaging (MR-\u002FCT-angiogram or DSA) on admission to rule out high suspicion of macrovascular bleeding source\n* Enrolment no later than 6 hours of symptom onset\n* Age \\>18 years, no upper age limit\n* Informed consent as documented by signature or fulfilling the criteria for emergency consent\u002F deferral consent\n\nExclusion Criteria:\n\n* Palliative care\u002Fcomfort therapy decision in the emergency department\n* ICH due to trauma (major head trauma \\\u003C24 hours of symptom onset causing loss of consciousness and thought to be sufficient to have caused the intracerebral bleeding)\n* High suspicion of ICH due to arteriovenous malformation (AVM), aneurysm or sinus-venous-thrombosis confirmed by neuroimaging, brain tumor, vasculitis, RCVS\u002FPRES or system disease (liver disease, inherit coagulopathy)\n* Severe ICH (haematoma volume \\>60ml or GCS \\\u003C8)\n* Haematoma evacuation or decompressive craniectomy within 72 hours planned or highly likely (isolated EVD is not an exclusion criterion)\n* Severe pre-morbid disability \\[modified Rankin scale (mRS) is ≥4\\]\n* Contraindication against the use of tranexamic acid\n* Active participation in another drug or devices trial concurrently\n* Female patient that are either pregnant or breastfeeding\n* Contraindications against Clevidipine (allergy to soja, lipid metabolism defect or known severe aortic stenosis)","100 Years",{"count":405,"type":22},[25],"The MAX-ICH pilot trial is a phase-II study aimed at assessing the feasibility and safety of a comprehensive care bundle for patients with intracerebral hemorrhage (ICH). This \"maximal medical treatment\" approach combines advanced interventions like intensive blood pressure control, rapid anticoagulation reversal, and tranexamic acid administration to potentially improve outcomes. The primary objective is to evaluate recruitment feasibility over 12 months, while secondary objectives include protocol adherence, safety monitoring, and the exploration of clinical outcomes. The study focuses on the critical first 72 hours of care to determine if this approach can be effectively implemented in clinical practice.",[439],"Intra Cerebral Hemorrhage","2026-06-30",{"date":314,"type":37},{"date":443,"type":37},"2025-08-07",{"date":445,"type":22},"2028-11-30",{"name":43,"class":44},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":193,"sex":18,"minAge":19,"maxAge":454,"enrollmentInfo":455,"targetDuration":4,"studyType":23,"phases":456,"briefSummary":457,"conditions":458,"keywords":460,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":45},"100641319","phase-4-calcitonin-gene-related-peptide-antibody-in-acute-mountain-sickness-100641319","NCT07653516","Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness","Calcitonin Gene-Related Peptide Antibody for Prevention of Acute Mountain Sickness: A Prospective Single-center, Randomized, Placebo-controlled, Double-blinded Study","Inclusion Criteria:\n\n* Age 18-60 years\n* No relevant previous illnesses in the preliminary examination\n* Written consent to participate in the study\n* Permanent residence \\\u003C1000 m\n* Men and women are included without prioritization\n* Negative urine pregnancy test if pregnancy cannot be ruled out with certainty\n\nExclusion Criteria:\n\n* Intolerance \u002F allergy to Fremanzeumab or other drug components\n* Acute or chronic lung disease\n* Blood pressure systolic ≥150 mmHg or diastolic ≥95 mmHg (average of two measurements) in subjects with or without blood pressure medication\n* Pre-existing cardiovascular diseases other than arterial hypertension (coronary heart disease, heart failure, pulmonary hypertension, atrial fibrillation, peripheral arterial occlusive disease)\n* Chronic headache, migraine\n* Diabetes mellitus\n* Smoking (\\>6 cigarettes\u002Fd) or equivalent nicotine substitution\n* Alcohol (\\>30 g\u002Fd) or other drug abuse\n* Overweight (BMI \\>30 kg\u002Fm2)\n* Other pre-existing conditions considered relevant by the investigators (liver disease, kidney disease, thyroid disease, Parkinson's disease, pheochromocytoma)\n* Stay \\>2000 m altitude within the last 8 weeks before the first study day\n* Medication taken within the last 2 months before the first study day, which could influence the data quality (e.g. corticosteroids) or the safety of the subjects (e.g. anticoagulation).\n* Blood donation within the last 2 months before the first study day\n* Pregnancy or breastfeeding\n* Participation in other clinical studies","60 Years",{"count":277,"type":22},[330],"Acute mountain sickness (AMS) is a common condition that can occur when healthy people travel quickly to high altitude. Typical symptoms include headache, nausea, tiredness, dizziness, and poor sleep. In most cases, AMS improves with rest and by not climbing higher, but it can make mountaineering difficult and, in severe cases, can lead to dangerous complications.\n\nThe biological mechanisms that cause high-altitude headache and AMS are not yet fully understood. Some symptoms of AMS are similar to migraine, suggesting that both conditions may share common pathways in the nervous system. One possible pathway involves calcitonin gene-related peptide (CGRP), a substance known to play an important role in migraine.\n\nFremanezumab is an approved monoclonal antibody used to prevent migraine. It works by binding to CGRP and reducing its biological activity. This study will investigate whether a single dose of fremanezumab can also help prevent symptoms of AMS and high-altitude headache in healthy adults exposed to high altitude. To date, there are no clinical data on the effect of fremanezumab in AMS or high-altitude headache.\n\nThis is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial. A total of 30 healthy adult volunteers will participate. Participants will be randomly assigned in a 1:1 ratio to receive either a single subcutaneous injection of fremanezumab 225 mg or placebo (saline). Neither the participants nor the investigators will know which treatment was given during the study. The study medication will be administered 1 week before ascent to Capanna Regina Margherita at 4554 meters above sea level. Participants will remain there for 46 hours under hypobaric hypoxic conditions.\n\nThe main goal is to determine whether fremanezumab reduces the severity of AMS compared with placebo. AMS symptoms will be measured using the Lake Louise Score, a standard questionnaire commonly used in altitude medicine. Additional assessments will include the incidence of AMS, headache characteristics, safety outcomes, vital signs, oxygen saturation, and the use of rescue medication. Symptoms will be assessed repeatedly during the high-altitude stay.\n\nOnly healthy adults aged 18 to 60 years living below 1000 meters will be eligible. People with important medical conditions, chronic headache or migraine, relevant cardiovascular or lung disease, pregnancy, or recent high-altitude exposure will be excluded. Participants will be closely monitored during the study. Rescue medication, oxygen, and descent to lower altitude will be available if needed.\n\nThis study may help improve understanding of how AMS develops and whether CGRP blockade could become a new preventive strategy for high-altitude headache and AMS. It may also improve understanding of links between altitude-related headache and migraine.",[459],"Acute Mountain Sickness",[461,462,463],"acute mountain sickness","calcitonin gene-related peptide antibody","migraine","2026-06-29",{"date":466,"type":37},"2026-07-01",{"date":468,"type":22},"2027-06-01",{"date":470,"type":22},"2027-07-31",{"name":43,"class":44},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":18,"minAge":480,"maxAge":19,"enrollmentInfo":481,"targetDuration":4,"studyType":23,"phases":482,"briefSummary":483,"conditions":484,"keywords":486,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":45},"100633992","fecal-microbiome-signature-of-multi-strain-probiotics-supplementation-in-children-and-adolescents-with-inflammatory-bowel-disease-100633992","NCT07533890","Fecal Microbiome Signature of Multi-Strain Probiotics Supplementation in Children and Adolescents With Inflammatory Bowel Disease","Fecal Microbiome Signature of Multi-Strain Probiotics Supplementation in Children and Adolescents With Inflammatory Bowel Disease - an Explanatory 1:1 Randomized Controlled Cross-Over Proof-of-Concept Trial With Blinded Outcome Assessment","MicroSig","Inclusion Criteria:\n\n* Signed informed consent\n* Diagnosis of inflammatory bowel disease according to actual guidelines (Porto Criteria)\n* General good health\n* Ability to understand and follow study procedures and understand informed consent\n* Age 5 -18 years\n* No probiotic therapy 4 weeks before entering into the study.\n\nExclusion Criteria:\n\n* Participation in other clinical studies interfering with study procedures.\n* Inability or contraindications to undergo the investigated intervention\n* Severe or acute flare of disease (for UC PUCAI score ≥35, for CD wPCDAI \\>40)\n* Treatment escalation within last 4 weeks for uncontrolled disease.\n* Antibiotic or probiotic therapy within the last 4 weeks.","5 Years",{"count":231,"type":22},[25],"In this study the intestinal microbiome and metabolic profiles of patients with inflammatory bowel disease will be determined upon probiotic intervention.",[485],"Inflamatory Bowel Disease",[487,488,489],"microbiome","inflammatory bowel disease","probiotics",{"date":440,"type":37},{"date":492,"type":37},"2026-05-01",{"date":494,"type":22},"2028-12",{"name":43,"class":44},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":504,"minAge":4,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":197,"phases":4,"briefSummary":507,"conditions":508,"keywords":511,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":522,"leadSponsor":524,"locationsCount":45},"100629735","stockholm3-test-validation-in-men-on-active-surveillance-in-switzerland-chas3-trial-100629735","NCT07478536","Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)","Multicenter Validation of the Stockholm3 Test on Men on Active Surveillance: the CHAS3-Trial","CHAS3","Inclusion Criteria:\n\n* Adult Men ≥ 18 y. o.\n* Men with low-risk prostate cancer (D'Amico risk classification) currently undergoing Active Surveillance (AS)\n* First inclusion in Active Surveillance (AS) after 1st January 2022.\n* Scheduled for follow-up with systematic and\u002For Magnetic Resonance Imaging (MRI)-targeted (fusion) prostate biopsies - Prostate Magnetic Resonance Imaging (MRI) performed within the past three months available\n\nExclusion Criteria:\n\n* \\- Prior prostate cancer treatment (surgery, radiation, chemotherapy, hormonal therapy).\n\n  * Patient with intermediate- or high-risk prostate cancer\n  * Urinary catheterization within the past 6-8 weeks\n  * Contraindications to Magnetic Resonance Imaging (MRI) or biopsy","MALE",{"count":506,"type":22},350,"The CHAS3 trial studies whether the Stockholm3 blood test can reliably detect if prostate cancer becomes more aggressive in men who are being carefully monitored instead of treated right away (active surveillance). The goal is to see if this test can help doctors safely follow patients with fewer invasive procedures, such as repeated biopsies.",[509,510],"Prostate Cancer","Active Surveillance for Prostate Cancer",[512,513,514,515,516,517],"Prostate","Cancer","Active Surveillance","Stockholm3","MRI","Biopsie","2026-06-18",{"date":520,"type":37},"2026-06-22",{"date":466,"type":22},{"date":523,"type":22},"2028-08-31",{"name":43,"class":44},{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":18,"minAge":533,"maxAge":80,"enrollmentInfo":534,"targetDuration":4,"studyType":23,"phases":536,"briefSummary":537,"conditions":538,"keywords":543,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":4},"100641331","digitally-assisted-rehabilitation-at-home-for-older-adults-after-hip-surgery-grimsel-100641331","NCT07658664","Digitally Assisted Rehabilitation at Home for Older Adults After Hip Surgery (GRIMSEL)","Digitally Assisted Geriatric Home-rehabilitation in Older Patients After Hip Surgery (GRIMSEL): a Non-inferiority Randomized Controlled Trial","GRIMSEL","Inclusion Criteria:\n\n* Community-dwelling adults aged 55 to 80 years\n* Hospitalized for hip surgery with unrestricted weight bearing at University Hospital Bern\n\nExclusion Criteria:\n\n* Discharge to inpatient rehabilitation\n* inability to comply with a rehabilitation program (e.g. comorbidity that prevents 30min light workout, major cognitive impairment)\n* end-of life situation","55 Years",{"count":535,"type":22},66,[25],"The goal of this clinical trial is to learn if a 12-week digitally supported, multimodal home rehabilitation program using the medical application Akina is as effective compared to routine care regarding functional independence in older adults undergoing hip surgery.\n\nHow is this multimodal home rehabilitation program received by patients? Is this multimodal home program at least as effective in terms of functional indpendence, muscle status, mobility and quality of life compared to routine care?\n\nResearchers will compare the multimodal rehabilitation program using the application Akina to routine care to see if the program works to treat patients after hip surgery.\n\nParticipants will:\n\nUndergo the rehab program at home or receive routine care (outpatient physiotherapy) for 12 weeks Visit the clinic after 6 and 12 weeks",[539,540,541,542],"Hip Surgery","Rehabilitation Program","Geriatrics Rehabilitation","Digital Health Intervention",[544,545,546,547],"functional independence","home-based rehabilitation","self-management","orthogeriatrics","2026-06-16",{"date":520,"type":37},{"date":551,"type":22},"2026-08",{"date":553,"type":22},"2028-08",{"name":43,"class":44},{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":565,"briefSummary":566,"conditions":567,"keywords":578,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":596},"100603978","early-exercise-based-rehabilitation-in-patients-hospitalized-for-acute-pulmonary-embolism-100603978","NCT07143539","Early Exercise-Based Rehabilitation in Patients Hospitalized for Acute Pulmonary Embolism","Early Exercise-based Rehabilitation in High-risk Patients Hospitalized for Acute Pulmonary Embolism: a Pragmatic Multicenter Randomized Partially Blinded Superiority Trial","RehabPE","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Hospitalization for objectively confirmed acute symptomatic PE, defined as intraluminal filling defect of a segmental or more proximal pulmonary artery on computed tomography pulmonary angiography (CTPA) or a high-probability ventilation-perfusion scintigraphy, and admission within the past 7 days\n3. Increased risk for post-PE syndrome, defined as simplified Pulmonary Embolism Severity Index (sPESI) ≥1 point at the time of admission\n4. Written informed consent\n\nExclusion Criteria:\n\n1. Contraindication to EBR (known unstable cardiac conditions like angina pectoris, severe valvular heart disease, or severe resting pulmonary hypertension)\n2. Medical condition that clearly precludes participation in EBR (e.g., inability to walk, unstable joints, severe neurological impairment)\n3. Recently completed (i.e., \\\u003C6 months), ongoing, or planned in- or outpatient EBR, or planned supervised outpatient physiotherapy for any indication\n4. Planned hospitalization during follow-up (e.g., elective surgery or inpatient chemotherapy)\n5. Contraindication to anticoagulation\n6. Life expectancy \\\u003C1 year based on the treating physician's clinical judgement\n7. Known pregnancy\n8. Inability to speak German or French\n9. Participation in another study that prohibits concurrent participation in RehabPE\n10. Unable to provide informed consent (e.g., due to dementia)\n11. Unwilling to provide informed consent\n12. Prior enrollment in this study",{"count":564,"type":22},160,[25],"Up to half of patients with pulmonary embolism (PE) suffer from impaired quality of life, reduced physical capacity, and symptoms like shortness of breath even three months after diagnosis, despite standard treatment with anticoagulation (blood thinners). The randomized RehabPE trial investigates whether an early, structured rehabilitation program with physical training and patient education can prevent such long-term effects.\n\nThe study includes hospitalized patients with acute symptomatic PE who are at increased risk of impaired quality of life three months after diagnosis. After informed consent, patients are randomly assigned to one of two groups: one receives an early 6-8-week, center-based rehabilitation program; the other receives standard follow-up care without rehabilitation. The intervention group completes 16-18 outpatient sessions of endurance and strength training, along with two education sessions covering the condition, treatment, and symptom management.\n\nOver 180 days, changes in quality of life, physical exercise capacity, breathlessness, and psychological symptoms, and the time to return to work \u002F usual daily activities will be monitored and compared between groups.",[568,569,570,571,572,573,574,575,576,577],"Venous Thromboembolism (VTE)","Exercise Therapy","Quality of Life (QOL)","Anxiety Depression","Humans","Exercise Tolerance","Rehabilitation Exercise","Dyspnea","Functional Status","Pulmonary Embolism (Diagnosis)",[579,580,581,582,583,584,585,586,587],"pulmonary embolism","deep vein thrombosis","excercise-based rehabilitation","post-PE syndrome","health-related quality of life","anxiety","depression","dyspnea","impact of early excercise-based rehabilitation","2026-06-11",{"date":590,"type":37},"2026-06-12",{"date":592,"type":37},"2025-12-17",{"date":594,"type":22},"2028-06",{"name":43,"class":44},6,{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":603,"eligibilityCriteria":604,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":605,"targetDuration":4,"studyType":197,"phases":4,"briefSummary":607,"conditions":608,"keywords":610,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":623},"100146616","swiss-diabetes-registry---swissdiab-study-100146616","NCT01179815","Swiss Diabetes Registry - SwissDiab Study","Swiss Diabetes Registry - SwissDiab Study, a Prospective Cohort Study of Patients With Diabetes in Switzerland","SwissDiab","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of diabetes mellitus according to ADA criteria\n* Informed consent\n\nExclusion Criteria:\n\n* Patients with gestational diabetes mellitus, patients unable to give informed consent, legally incompetent or incapable to comply with the study terms and conditions as well as patients with significantly reduced life expectancy (\\\u003C1 year) will be excluded",{"count":606,"type":22},1500,"Currently, the estimated number of people with diabetes mellitus is approximately 387 million people worldwide. Due to population growth, urbanization, ageing and the rising prevalence of obesity the numbers of individuals with diabetes is increasing likewise. It has been shown that improving glycemic control is associated with a reduction in late complications of diabetes, such as cardiovascular and microvascular diseases. Therefore, treatment guidelines were established internationally by large and renowned associations and adopted by many countries.\n\nFor Switzerland only sparse data exist on the actual implementation of such recommendations and on patient's well-being. The Swiss Diabetes Registry - SwissDiab Study is a prospective cohort study aiming at including and collecting data of virtually all patients regularly seen and treated at the study centers (≈ 500 patients each), irrespective of type, duration of diabetes or treatment . This allows the evaluation of diabetes treatment strategies at these centers. Furthermore, risk indicators for micro- and macrovascular complications, mortality as well as costs and quality of life will be assessed. Data will be recorded through an internet-based, electronic database specifically designed for this study. At a later perspective it is planned to extend data collection to general practitioner\u002Ffamily doctor networks in order to include a larger and more representative sample of patients with diabetes in Switzerland.",[609],"Diabetes Mellitus",[611,612,613,614,615],"Patients with type 1 or type 2 diabetes mellitus","Monogenetic diabetes","Pancreatogenic diabetes,","Drug-induced diabetes, other forms","Cohort Studies","2026-06-08",{"date":588,"type":37},{"date":619,"type":4},"2010-01",{"date":621,"type":22},"2099-01",{"name":43,"class":44},4,{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":630,"eligibilityCriteria":631,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":197,"phases":4,"briefSummary":634,"conditions":635,"keywords":637,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":646,"leadSponsor":647,"locationsCount":45},"100637995","mirna-quantification-in-patients-with-septic-shock-100637995","NCT07597122","MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK","MIRSEP - MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK","MIRSEP","Inclusion Criteria:\n\nSeptic shock:\n\n* New onset (\\\u003C24h) of septic shock diagnosis according to Sepsis-3 definition\n* (suspected) infection\n* Vasopressors required to maintain mean arterial pressure ≥65mm Hg (despite adequate fluid resuscitation)\n* Serum lactate level \\> 2mmol\u002FL\n* Minimum age of 18 years\n* Expected length of stay \\>48h\n* Written consent from an independent physician\n\nCritically ill:\n\n* Patients on mechanical ventilation (MV) in the ICU without an admission diagnosis of sepsis\u002Fseptic shock according to Sepsis-3 definition\n* Minimum age of 18 years\n* Expected length of stay \\>48h\n* Written consent from an independent physician\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Patients known not to speak German or French\n* Patients with known.\n\n  1. Pre-existing congenital or acquired severe immune deficiency (e.g. severe combined immunodeficiency, HIV infection, AIDS) or\n  2. current immunosuppressive therapy (immunosuppressive biologicals or active lymphocyte therapy e.g. endoxan, rituximab or corticosteroid use at a dose \\> 10 mg\u002Fday equivalent of prednisone. However, acute corticosteroid treatment of a relative adrenal insufficiency using a maximum hydrocortisone dose of 200 mg\u002Fday is accepted.",{"count":633,"type":22},56,"Sepsis-induced immunosuppression (SIS) is a common complication in patients with septic shock. Reduced expression of Human leukocyte antigen isotype DR (HLA-DR) on circulating monocytes is a marker for SIS and correlates with risk of secondary infections and mortality. The miRSep study aims to improve the understanding of early microRNA (miRNA) mediated changes in HLA-DR on monocytes in patients with septic shock.",[636],"Sepsis and Septic Shock",[638,639,640,641,642],"Septic shock","Sepsis induced immunusuppression","HLA-DR","miRNA","Monocytes",{"date":644,"type":37},"2026-06-02",{"date":180,"type":37},{"date":219,"type":22},{"name":43,"class":44},{"id":649,"slug":650,"hasResults":12,"nctId":651,"briefTitle":652,"officialTitle":653,"acronym":4,"eligibilityCriteria":654,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":655,"targetDuration":4,"studyType":23,"phases":657,"briefSummary":658,"conditions":659,"keywords":662,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":669,"lastUpdatePostDateStruct":670,"startDateStruct":671,"completionDateStruct":673,"leadSponsor":675,"locationsCount":45},"100640405","litt-for-ultra-early-gbm-recurrence-100640405","NCT07616986","LITT for Ultra-early GBM Recurrence","Laser Interstitial Thermal Therapy for Ultra-Early, Pre-Radiotherapy Glioblastoma Recurrence","Inclusion Criteria:\n\n* Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status\n* ≥18 years of age\n* CRET\n* Karnofsky Performance Status (KPS) ≥70\n* No contra-indication for radio-chemotherapy\n* Scheduled for adjuvant radio-chemotherapy at University Hospital of Bern\n* Able to provide informed consent\n* No contra-indication for LITT\n* No pregnancy or active breast-feeding\n* No known coagulopathy independent of medication\n* No dissemination or multifocal disease\n* Patients lacking capacity to consent or considered vulnerable (e.g., minors, those under legal protection) are not included.\n\nExclusion Criteria:",{"count":656,"type":22},12,[25],"Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT\u002FCT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy.\n\nLITT offers a minimally invasive alternative that may:\n\n* Treat recurrence without delaying RT\u002FCT\n* Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-week window between pre-RT MRI and radiotherapy initiation, maintaining the adjuvant schedule.",[660,661],"Glioblastoma (GBM)","Glioblastoma - Category",[663,664,665,666,667,668],"LITT","Laser Interstitial Thermal Therapy","ultra-early recurrence","GMB","GMB recurrence","GMB ultra-early recurrence","2026-05-28",{"date":180,"type":37},{"date":672,"type":37},"2026-02-06",{"date":674,"type":22},"2028-01-31",{"name":43,"class":44},{"id":677,"slug":678,"hasResults":12,"nctId":679,"briefTitle":680,"officialTitle":681,"acronym":682,"eligibilityCriteria":683,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":684,"enrollmentInfo":685,"targetDuration":4,"studyType":23,"phases":687,"briefSummary":688,"conditions":689,"keywords":691,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":696,"lastUpdatePostDateStruct":697,"startDateStruct":699,"completionDateStruct":701,"leadSponsor":702,"locationsCount":244},"100545791","acceptability-of-the-somnomat-casa-for-the-treatment-of-parkinsons-disease-100545791","NCT06386497","Acceptability of the Somnomat Casa for the Treatment of Parkinson's Disease","Overnight Treatment of Parkinson's Disease Using Vestibular Stimulation From a Rocking Bed (Somnomat Casa) - A Feasibility Study","Somnomat Casa","Inclusion Criteria:\n\n* Informed Consent signed by the subject\n* PD according to the MDS clinical diagnostic criteria for Parkinson's disease\n* Suffering from reduced sleep quality as defined by pathological cut-off (score of \\> 5) on the Pittsburgh Sleep Quality Index (PSQI)\n* Patients with stable antiparkinsonian, antidepressant, and sleep medications for six weeks before intervention and maintained on stable medication during the intervention period\n* Treatment without bilateral deep brain stimulation\n* Fluent in German\n\nExclusion Criteria:\n\n* Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.).\n* Dementia as defined by a MOCA score lower than 24\u002F30\n* Weight \\> 150kg\n* Depression with acute suicidal ideation\n* Presence of major ongoing psychiatric illness such as acute non-controlled psychosis\n* Poor general health (e.g. non-controlled diabetes, uncontrolled arterial hypertension, therapy for malignancy)\n* Inability to follow the procedures of the study, e.g. filling out patient questionnaires due to language problems, psychological disorders, dementia, etc. of the participant\n* Participation in another interventional trial within the 30 days preceding and during the present study\n* Participants with PSQI score lower or equal 5","85 Years",{"count":686,"type":22},15,[25],"This pilot study aims to evaluate the feasibility and acceptability of nocturnal translational vestibular stimulations (VS) applied by a rocking bed (Somnomat Casa) for two months in patients with Parkinson's Disease.",[690],"Parkinson Disease",[692,693,694,695],"Vestibular Stimulation","Sleep quality","Rocking bed","Feasibility","2026-05-21",{"date":698,"type":37},"2026-05-22",{"date":700,"type":37},"2024-01-11",{"date":219,"type":22},{"name":43,"class":44},""]